Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Jazz Pharmaceuticals PLC (JAZZ) had Revenue of $3.83B for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$3.83B
Net Income	$439.71M
Cost of Goods Sold	$435.58M
Gross Profit	$3.40B
Operating Expenses	$3.26B
Operating Income	$578.58M
Non-Operating Income/Expense	$-280.65M
Pre-Tax Income	$297.93M
Normalized Pre-Tax Income	$297.93M
Income after Taxes	$417.84M
Income from Continuous Operations	$414.83M
Consolidated Net Income/Loss	$414.83M
Normalized Income after Taxes	$417.84M
EBIT	$578.58M
EBITDA	$1.22B
Weighted-Average Shares Outstanding (Basic)	63.29M
Weighted-Average Shares Outstanding (Diluted)	72.07M
Earnings per Share (EPS) (Basic)	$6.55
Earnings per Share (EPS) (Diluted)	$6.10
Balance Sheet Financials
Current Assets	$3.44B
Property, Plant, and Equipment	$169.65M
Long-Term Assets	$7.96B
Total Assets	$11.39B
Current Liabilities	$1.54B
Long-Term Debt	$5.11B
Long-Term Liabilities	$6.12B
Total Liabilities	$7.66B
Common Equity	$3.74B
Tangible Shareholders Equity	$-3.43B
Shareholders Equity	$3.74B
Common Shares Outstanding	62.26M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.09B
Cash Flow from Investing Activities	$-163.06M
Cash Flow from Financial Activities	$-305.25M
Beginning Cash	$881.48M
End Cash	$1.51B
Increase/Decrease in Cash	$624.83M
Stock-Based Compensation	$226.84M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.24
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.58
Debt to Equity Ratio	1.53
Gross Margin	88.64%
Operating Margin	15.09%
EBIT Margin	15.09%
EBITDA Margin	31.75%
Pre-Tax Profit Margin	7.77%
Profit Margin	11.47%
Free Cash Flow	$1.07B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	0.73
Receiveable Turnover	5.43
Days Sales in Receivables	67.19
Return on Equity	11.10%
Return on Tangible Equity	-12.08%
Return on Assets	3.64%
Return on Investments	4.69%
Book Value Per Share	$60.03
Free Cash Flow per Share	$14.82
Operating Cash Flow per Share	$15.15

Data from Zacks Investment Research, Inc.